{
  "schema_version": 1,
  "kind": "drug_profile",
  "generic": "verapamil",
  "review_status": "reviewed",
  "origin": "openfda",
  "sections": {
    "adult": [
      {
        "text": "The usual daily dose of sustained-release verapamil, verapamil hydrochloride sustained-release capsules, in clinical trials has been 240 mg given by mouth once daily in the morning.",
        "source": "US FDA label for verapamil (Verapamil Hydrochloride), section 'dosage and administration', retrieved 2026-08-29",
        "cached_file": "labels/verapamil.json",
        "verbatim": true
      },
      {
        "text": "However, initial doses of 120 mg a day may be warranted in patients who may have an increased response to verapamil (e.g., elderly, small people, etc.).",
        "source": "US FDA label for verapamil (Verapamil Hydrochloride), section 'dosage and administration', retrieved 2026-08-29",
        "cached_file": "labels/verapamil.json",
        "verbatim": true
      },
      {
        "text": "If adequate response is not obtained with 120 mg of verapamil hydrochloride sustained-release capsules, the dose may be titrated upward in the following manner: (a) 180 mg in the morning.",
        "source": "US FDA label for verapamil (Verapamil Hydrochloride), section 'dosage and administration', retrieved 2026-08-29",
        "cached_file": "labels/verapamil.json",
        "verbatim": true
      }
    ],
    "child": [
      {
        "text": "Safety and efficacy of verapamil in children below the age of 18 years have not been established.",
        "source": "US FDA label for verapamil (Verapamil Hydrochloride), section 'pediatric use', retrieved 2026-08-29",
        "cached_file": "labels/verapamil.json",
        "verbatim": true
      }
    ],
    "renal": [
      {
        "text": "No kidney-impairment dose in this label. Not a statement that none is needed.",
        "source": "Read and found silent: the US FDA label for verapamil (Verapamil Hydrochloride), retrieved 2026-08-29",
        "cached_file": "labels/verapamil.json",
        "verbatim": false
      }
    ],
    "hepatic": [
      {
        "text": "No liver-impairment dose in this label. Not a statement that none is needed.",
        "source": "Read and found silent: the US FDA label for verapamil (Verapamil Hydrochloride), retrieved 2026-08-29",
        "cached_file": "labels/verapamil.json",
        "verbatim": false
      }
    ],
    "pregnancy": [
      {
        "text": "Reproduction studies have been performed in rabbits and rats at oral doses up to 1.5 (15 mg/kg/day) and 6 (60 mg/kg/day) times the maximum recommended human daily dose, respectively, and have revealed no evidence of teratogenicity.",
        "source": "US FDA label for verapamil (Verapamil Hydrochloride), section 'pregnancy', retrieved 2026-08-29",
        "cached_file": "labels/verapamil.json",
        "verbatim": true
      },
      {
        "text": "In the rat, however, this multiple of the human dose was embryocidal and retarded fetal growth and development, probably because of adverse maternal effects reflected in reduced weight gains of the dams.",
        "source": "US FDA label for verapamil (Verapamil Hydrochloride), section 'pregnancy', retrieved 2026-08-29",
        "cached_file": "labels/verapamil.json",
        "verbatim": true
      },
      {
        "text": "This oral dose has also been shown to cause hypotension in rats.",
        "source": "US FDA label for verapamil (Verapamil Hydrochloride), section 'pregnancy', retrieved 2026-08-29",
        "cached_file": "labels/verapamil.json",
        "verbatim": true
      }
    ],
    "lactation": [
      {
        "text": "Because of the potential for adverse reactions in nursing infants from verapamil, nursing should be discontinued while verapamil is administered.",
        "source": "US FDA label for verapamil (Verapamil Hydrochloride), section 'nursing mothers', retrieved 2026-08-29",
        "cached_file": "labels/verapamil.json",
        "verbatim": true
      }
    ]
  }
}